Cezar Health is involved in the medical equipment and healthcare industry, providing products and services related to hospitals, dental units, and consumer health. The company self-described as a participant in various healthcare conferences and has launched its own private label brand in the health sector.

Cezar Health

Biofourmis harnesses the power of technology and data to shape innovations that bring the right care to every person, no matter where they are. The company aims to make care simpler, science smarter, and patients healthier.

Xuejiao Zhao

Kuldeep Rajput

Maulik Majmudar

Biofourmis

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Metric
Company Name	Cezar Health	Biofourmis	Castle Biosciences, Inc.	Danaher Corporation
Symbol			CSTL	DHR
MSH ID	COM:CEZARHEALTH	COM:BIOFOURMIS	COM:CASTLEBIOSCIENCES	COM:DANAHER
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Medical Equipment and Supplies	Healthcare Technology	Medical - Diagnostics & Research	Medical - Diagnostics & Research
Country	PS	US	US	US
Stage
Employee Count		451	638	61K
Website	cezarhealth.com	biofourmis.com	castlebiosciences.com	danaher.com
LinkedIn		biofourmis		danaher
Founders

Metric
Market Cap	482.57M	179.39B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	219.79M	14.03B
Revenue (LTM)
Revenue (NTM)
Gross Profit	164.23M	14.03B
EBITDA	-55.65M	5.20B
Operating Income	-67.98M	5.20B
Net Income	-57.47M	4.74B
EPS	-2.14	6.44
Diluted EPS	-2.14	6.38
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80	0.67
Operating Profit Margin	-0.05	0.24
EBITDA Margin	-0.25	0.37
Net Profit Margin	-0.01	0.22
Return on Equity	-0.01	0.09
Return on Assets	-0.01	0.06
Return on Capital Employed	-0.04	0.06

CEZA

COM:CEZARHEALTH

Cezar Health

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.33	38.16
P/B Ratio	1.63	3.40
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.28	10.41
EV Multiple	10.23K	28.43

Metric
Days Sales Outstanding	70.34	57.32
Days Payables Outstanding	60.10	73.37
Days Inventory Outstanding	60.83	155.94
Operating Cycle	124.44	220.00
Cash Conversion Cycle	50.86	123.96
Asset Turnover	0.59	0.28

Metric
Operating Cash Flow	-135K	7.16B
Free Cash Flow	-13.76M	5.78B
Cash Flow to Debt	4.12	0.37
Operating Cash Flow/Sales	0.16	0.31
Free Cash Flow Yield	-0.07	0.03

Metric
Cash & Equivalents	98.84M	5.86B
Accounts Receivable	-14.93M	322M
Inventory	7.94M	2.59B
Goodwill	10.69M	41.61B
Debt to Capitalization	0.06	0.27
Debt to Assets	0.03	0.22
Current Ratio	7.70	1.68
Quick Ratio	9.02	1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.26	0.01
R&D to Revenue	0.27	0.07
SG&A to Revenue	0.33